Cutter Capital Management, L.P. is an investment fund managing more than $519 billion ran by Kerry Kourepenos. There are currently 25 companies in Mrs. Kourepenos’s portfolio. The largest investments include Bristol-Myers Squibb Co and Gilead Sciences, together worth $87.4 billion.
As of 30th July 2024, Cutter Capital Management, L.P.’s top holding is 893,800 shares of Bristol-Myers Squibb Co currently worth over $48.5 billion and making up 9.3% of the portfolio value.
Relative to the number of outstanding shares of Bristol-Myers Squibb Co, Cutter Capital Management, L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 530,872 shares of Gilead Sciences worth $38.9 billion, whose value fell 3.7% in the past six months.
The third-largest holding is Teva Pharmaceutical Inds Ltd worth $32 billion and the next is Regeneron Pharmaceuticals worth $31.5 billion, with 32,720 shares owned.
Currently, Cutter Capital Management, L.P.'s portfolio is worth at least $519 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Cutter Capital Management, L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Kerry Kourepenos serves as the COO at Cutter Capital Management, L.P..
In the most recent 13F filing, Cutter Capital Management, L.P. revealed that it had opened a new position in
Gilead Sciences and bought 530,872 shares worth $38.9 billion.
This means they effectively own approximately 0.1% of the company.
Gilead Sciences makes up
9.4%
of the fund's Health Care sector allocation and has decreased its share price by approximately 0.1% in the past year.
The investment fund also strengthened its position in Bristol-Myers Squibb Co by buying
753,800 additional shares.
This makes their stake in Bristol-Myers Squibb Co total 893,800 shares worth $48.5 billion.
Bristol-Myers Squibb Co dropped approximately 0.1% in the past year.
On the other hand, there are companies that Cutter Capital Management, L.P. is getting rid of from its portfolio.
Cutter Capital Management, L.P. closed its position in AMGEN on 6th August 2024.
It sold the previously owned 57,381 shares for $16.5 billion.
The two most similar investment funds to Cutter Capital Management, L.P. are Crane Advisory and Crow's Nest L.P.. They manage $519 billion and $519 billion respectively.
Cutter Capital Management, L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 80.2% of
the total portfolio value.
The fund focuses on investments in the United States as
68.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
28% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $25.9 billion.
These positions were updated on August 6th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Bristol-Myers Squibb Co. |
538.43%
893,800
|
$48,470,774,000 | 9.34% |
| Gilead Sciences, Inc. |
Opened
530,872
|
$38,886,374,000 | 7.50% |
| Teva Pharmaceutical Inds Ltd |
113.95%
2,271,420
|
$32,049,736,000 | 6.18% |
| Regeneron Pharmaceuticals, Inc. |
Opened
32,720
|
$31,492,672,000 | 6.07% |
| Biomarin Pharmaceutical Inc. |
169.43%
350,000
|
$30,569,000,000 | 5.89% |
| Ionis Pharmaceuticals Inc |
Opened
578,732
|
$25,088,032,000 | 4.84% |
| Royalty Pharma plc |
122.45%
823,080
|
$24,996,940,000 | 4.82% |
| Sarepta Therapeutics Inc |
Opened
188,758
|
$24,436,610,000 | 4.71% |
| Acadia Pharmaceuticals Inc |
297.86%
1,316,818
|
$24,347,964,000 | 4.69% |
| Biogen Inc |
Opened
104,000
|
$22,425,520,000 | 4.32% |
| Biocryst Pharmaceuticals Inc. |
176.70%
4,210,918
|
$21,391,464,000 | 4.12% |
| Halozyme Therapeutics Inc. |
112.14%
510,098
|
$20,750,786,000 | 4.00% |
| Perrigo Co Plc |
147.78%
644,228
|
$20,737,700,000 | 4.00% |
| Exelixis Inc |
72.51%
797,524
|
$18,925,244,000 | 3.65% |
| Avadel Pharmaceuticals plc |
Opened
1,083,852
|
$18,306,260,000 | 3.53% |
| Eli Lilly & Co |
Opened
22,080
|
$17,177,356,000 | 3.31% |
| Agios Pharmaceuticals Inc |
Opened
577,160
|
$16,876,158,000 | 3.25% |
| AMGEN Inc. |
Closed
57,381
|
$16,526,876,000 | |
| CRISPR Therapeutics AG |
123.60%
240,370
|
$16,383,620,000 | 3.16% |
| Arcellx Inc |
Opened
214,000
|
$14,883,700,000 | 2.87% |
| Merck & Co Inc |
Closed
136,098
|
$14,837,404,000 | |
| Amicus Therapeutics Inc |
Closed
947,418
|
$13,443,861,000 | |
| Insmed Inc |
9.96%
454,674
|
$12,335,306,000 | 2.38% |
| Roivant Sciences Ltd |
Closed
1,000,000
|
$11,230,000,000 | |
| Viridian Therapeutics Inc |
81.10%
557,276
|
$9,757,902,000 | 1.88% |
| Legend Biotech Corp |
Opened
159,660
|
$8,955,330,000 | 1.73% |
| Kyverna Therapeutics Inc |
Opened
333,028
|
$8,272,416,000 | 1.59% |
| Pfizer Inc. |
Closed
265,000
|
$7,629,350,000 | |
| Apellis Pharmaceuticals Inc |
Closed
108,000
|
$6,464,880,000 | |
| Pliant Therapeutics, Inc. |
Opened
388,238
|
$5,784,746,000 | 1.12% |
| Iovance Biotherapeutics Inc |
Closed
677,350
|
$5,506,856,000 | |
| Cabaletta Bio Inc |
37.36%
315,928
|
$5,389,732,000 | 1.04% |
| Prestige Consmr Healthcare I |
Closed
85,000
|
$5,203,700,000 | |
| BridgeBio Pharma Inc |
Closed
103,324
|
$4,171,190,000 | |
| Arcus Biosciences Inc |
Closed
192,667
|
$3,679,940,000 | |
| No transactions found | |||
| Showing first 500 out of 35 holdings | |||